OBJECTIVE: To systematically evaluate the efficacy and safety of Kuntai capsules combined with hormone replacement therapy（ HRT） in the treatment of premature ovarian failure based on the Meta-analysis method.METHODS: CNKI

VIP database

Wanfang database

CBM and PubMed were retrieved to collect the randomized controlled trials of Kuntai capsules combined with HRT in the treatment of premature ovarian failure（ the study group was treated with Kuntai capsules combined with HRT

while the control group received HRT）. The retrieval time was from establishment of the database to Dec. 31 st

2018. The risk of bias assessment tool was used for quality assessment. Meta-analysis was conducted on the levels of follicle-stimulating hormone（ FSH）

luteinizing hormone（ LH） and estradiol（ E

2

）

symptom score before and after treatment

total effective rate and incidence of adverse drug reactions by using RevMan 5. 3 software. RESULTS: Totally 15 literature were collected

including 1 343 patients.Meta analysis results showed that compared with HRT alone

Kuntai capsules combined with HRT can significantly reduce the levels of FSH（ MD =-7. 13

95% CI =-8. 08--6. 19

P

<

0. 000 01） and LH（ MD =-5. 43

95% CI=-6. 99--3. 88

P

<

0. 000 01）

significantly increase the levels of E

2

（ SMD = 1. 14

95% CI = 0. 73-1. 54

P

<

0. 000 01）

and significantly reduce the symptom score（ MD =-4. 42

95% CI =-5. 55--3. 28

P

<

0. 000 01）

significantly improve the total effective rate（ OR = 3. 53

95% CI = 2. 53-4. 94

P

<

0. 000 01） and safety（ OR =0. 56

95% CI = 0. 31-1. 01

P = 0. 05）

the differences were statistically significant. CONCLUSIONS: Kuntai capsules combined with HRT has obvious advantages

which can improve the clinical symptoms of patients with premature ovarian failure

reduce the adverse drug reactions

improve the safety

and can be used as the adjuvant treatment.